These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 24881914)

  • 21. Current opinions and controversies in chronic myeloid leukaemia.
    Kishore B; Marin D
    Curr Opin Oncol; 2011 Nov; 23(6):659-64. PubMed ID: 21918441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Breccia M; Colafigli G; Molica M; Alimena G
    Expert Opin Drug Saf; 2016; 15(4):525-33. PubMed ID: 26799331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
    Cea M; Cagnetta A; Garuti A; Cirmena G; Rocco I; Moran E; Grillo V; Ballestrero A; Patrone F; Nencioni A
    J BUON; 2009; 14(4):565-73. PubMed ID: 20148444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CML: imatinib mesylate (Glivec) or something else?
    Ghosh A
    Nepal Med Coll J; 2007 Dec; 9(4):292. PubMed ID: 18298026
    [No Abstract]   [Full Text] [Related]  

  • 25. Chronic myeloid leukemia-transplantation in the tyrosine kinase era.
    Innes AJ; Apperley JF
    Hematol Oncol Clin North Am; 2014 Dec; 28(6):1037-53. PubMed ID: 25459178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era.
    Kim DW; Banavali SD; Bunworasate U; Goh YT; Ganly P; Huang H; Irving I; Jootar S; Goh HG; Koh LP; Li W; Naoe T; Ng SC; Purushotaman V; Reksodiputro H; Shih LY; Tang JL; Tojo A; Wang J; Wong R
    Leuk Res; 2010 Nov; 34(11):1459-71. PubMed ID: 20430443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population-based study.
    Jamy O; Godby R; Sarmad R; Costa LJ
    Am J Hematol; 2021 Jul; 96(7):E265-E268. PubMed ID: 33864684
    [No Abstract]   [Full Text] [Related]  

  • 28. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.
    Wang W; Cortes JE; Lin P; Khoury JD; Ai D; Tang Z; Tang G; Jorgensen JL; Medeiros LJ; Hu S
    Leukemia; 2015 Nov; 29(11):2263-6. PubMed ID: 25931274
    [No Abstract]   [Full Text] [Related]  

  • 30. Chronic myeloid leukemia: how can minimal cytogenetic response after 3 months of treatment be classified according to the new European LeukemiaNet recommendations?
    Jiménez-Velasco A; Barrios M; Alcalá M; Heiniger AI
    J Clin Oncol; 2010 Jun; 28(18):e310; author reply e311. PubMed ID: 20479423
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
    Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
    J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
    [No Abstract]   [Full Text] [Related]  

  • 32. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Oyekunle A; Zander AR; Binder M; Ayuk F; Zabelina T; Christopeit M; Stübig T; Alchalby H; Schafhausen P; Lellek H; Wolschke C; Müller I; Bacher U; Kröger N
    Ann Hematol; 2013 Apr; 92(4):487-96. PubMed ID: 23250623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The DESTINY of chronic myeloid leukeamia.
    Abruzzese E
    Lancet Haematol; 2017 Jul; 4(7):e303-e304. PubMed ID: 28566210
    [No Abstract]   [Full Text] [Related]  

  • 35. Emerging drugs for chronic myeloid leukemia.
    Cilloni D; Messa E; Rotolo A; Saglio G
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):175-84. PubMed ID: 20201747
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM; Melo JV
    Acta Haematol; 2008; 119(4):212-7. PubMed ID: 18566539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should we also evaluate SET together with CIP2A for the treatment with second-generation tyrosine kinase inhibitors in chronic myeloid leukemia?
    Cristóbal I; Manso R; González-Alonso P; Rojo F; García-Foncillas J
    Leukemia; 2015 Oct; 29(10):2117. PubMed ID: 26283451
    [No Abstract]   [Full Text] [Related]  

  • 40. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.